EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Lanadelumab in Hereditary Angioedema: Extending Dose Intervals from Every 2 Weeks to Every 4 Weeks

Marc A Riedl, Daniel Soteres, Mark A Davis-Lorton, Tara Piccolo, Matt Otule, Irmgard Andresen, Timothy Craig

International Archives of Allergy and Immunology · 09.06.2026 · 1-12

DOI: 10.1159/000551678 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Archives of Allergy and Immunology, online erschienen am 09.06.2026. Verfasst von Marc A Riedl und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, California, USA. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Both clinical trial and real-world data demonstrate the effectiveness of lanadelumab long-term prophylaxis (LTP) to prevent hereditary angioedema (HAE) attacks, which may be maintained after dose interval extension from every 2 weeks (Q2W) to every 4 weeks (Q4W) in patients with well-controlled disease (attack free for >6 months). Summary: This narrative review summarizes published data on lanadelumab treatment patterns collected from clinical trials and observational studies since US approval in 2018. Disease activity and HAE-related healthcare resource use at baseline and during the first 6 months of lanadelumab treatment may be useful indicators of patients with well-controlled disease who will be eligible for, and may derive benefit from, dose interval extension on lanadelumab. Patients who receive a dose interval extension could benefit from a reduction in treatment burden, but not all patients may be a good fit for interval extension. Key Messages: Although there are inherent limitations related to analyzing small sample sizes for subgroups of patients with a rare disease and for data derived from real-world studies, these data can inform physicians and patients about the characteristics and outcomes of patients who have successfully extended dosing intervals of lanadelumab LTP. This may in turn encourage regular monitoring to facilitate optimization of treatment and outcomes for each patient.

Schlagwörter

Stichwörter der Autor:innen

DosingHereditary angioedemaLanadelumabQ4W

Autor:innen und Institutionen

  • Division of Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Asthma and Allergy Associates, Colorado Springs, Colorado, USA.
  • ENT and Allergy Associates, Tarrytown, New York, USA.
  • Takeda Pharmaceuticals USA, Inc., Lexington, Massachusetts, USA.
  • Takeda Pharmaceuticals International AG, Zurich, Switzerland.
  • Allergy, Asthma and Immunology, Departments of Medicine, Pediatrics, MFM, and Biomedical Sciences, Director ACARE International Hereditary Angioedema Resource Center, Penn State University, Hershey, Pennsylvania, USA, t…

Zitieren

APA

Riedl, M. A., Soteres, D., Davis-Lorton, M. A., Piccolo, T., Otule, M., Andresen, I., & Craig, T. (2026). Lanadelumab in Hereditary Angioedema: Extending Dose Intervals from Every 2 Weeks to Every 4 Weeks. International Archives of Allergy and Immunology, 1-12. https://doi.org/10.1159/000551678

Vancouver

Riedl MA, Soteres D, Davis-Lorton MA, Piccolo T, Otule M, Andresen I, et al. Lanadelumab in Hereditary Angioedema: Extending Dose Intervals from Every 2 Weeks to Every 4 Weeks. International Archives of Allergy and Immunology. 2026:1-12. doi:10.1159/000551678

BibTeX
@article{Riedl2026,
  author = {Riedl, Marc A and Soteres, Daniel and Davis-Lorton, Mark A and Piccolo, Tara and Otule, Matt and Andresen, Irmgard and Craig, Timothy},
  title = {Lanadelumab in Hereditary Angioedema: Extending Dose Intervals from Every 2 Weeks to Every 4 Weeks},
  journal = {International Archives of Allergy and Immunology},
  year = {2026},
  pages = {1--12},
  doi = {10.1159/000551678}
}
Kostenlos starten →